Antigen Discovery, Inc., founded in Irvine, United States, is dedicated to advancing the field of immunology through the identification of biomarkers for disease protection. Their core mission is to leverage proteomic technologies to develop customized solutions for infectious diseases, with a particular focus on malaria. By utilizing cutting-edge proteomic tools, they aim to provide innovative diagnostic and therapeutic products that address critical global health challenges.
Notable achievements include being awarded a Phase II SBIR grant to identify biomarkers associated with malaria protection, underscoring their impact in the field. The company collaborates with leading researchers and institutions to drive its mission forward. Through their pioneering work, Antigen Discovery, Inc. has made significant strides in improving disease diagnostics and contributing to global health advancements.
